<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05025111</url>
  </required_header>
  <id_info>
    <org_study_id>304718</org_study_id>
    <nct_id>NCT05025111</nct_id>
  </id_info>
  <brief_title>Entia Liberty: Capillary Validation</brief_title>
  <official_title>Entia Liberty: Clinical Performance Validation - Capillary Performance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Entia Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Entia Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a clinical performance validation study to evaluate the performance of the&#xD;
      Entia Liberty device. Patients undergoing routine venepuncture blood tests will be recruited&#xD;
      to have an Entia Liberty test (by finger-prick) done on them by a trained healthcare&#xD;
      professional. The results from that finger-prick test will be compared against the results&#xD;
      from the routine venepuncture blood test (reference method) and subsequently, excess blood&#xD;
      from the routine venepuncture test will be run on another Entia Liberty device in the&#xD;
      laboratory. All three results (Entia Liberty capillary, Entia Liberty venous and gold&#xD;
      standard venous) will be compared against each other to prove Entia Liberty's performance&#xD;
      claims.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To obtain/validate the value of the total error of the Entia Liberty device.</measure>
    <time_frame>3 months</time_frame>
    <description>The dataset from this study will provide evidence to support the device's performance claims.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To obtain/validate the value of the linearity of the Entia Liberty device.</measure>
    <time_frame>3 months</time_frame>
    <description>The dataset from this study will provide evidence to support the device's performance claims.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To obtain/validate the value of the bias of the Entia Liberty device.</measure>
    <time_frame>3 months</time_frame>
    <description>The dataset from this study will provide evidence to support the device's performance claims.</description>
  </primary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Entia Liberty</intervention_name>
    <description>Home monitoring device</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants will be recruited from the outpatients clinic at the Christie, while they are&#xD;
        waiting for their blood tests.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years old at the time of study entry&#xD;
&#xD;
          -  Currently receiving standard of care systemic anti- cancer therapy (chemotherapy,&#xD;
             immunotherapy, endocrine and targeted therapy) for solid organ malignancy and has&#xD;
             received at least one cycle.&#xD;
&#xD;
          -  Scheduled to be undergoing routine venous laboratory blood tests as part of standard&#xD;
             of care&#xD;
&#xD;
          -  Can provide written informed consent&#xD;
&#xD;
          -  Blood samples collected and stored in K2-EDTA vacutainers only&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known inherited or acquired bleeding disorder&#xD;
&#xD;
          -  History of haematological malignancy&#xD;
&#xD;
          -  Known poorly controlled anti-coagulation&#xD;
&#xD;
          -  Inadequate use and understanding of the English language, requiring a translator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 26, 2021</study_first_submitted>
  <study_first_submitted_qc>August 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2021</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

